Back to News
Market Impact: 0.25
Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance
Source: Nasdaq
Corporate Guidance & OutlookCompany FundamentalsHealthcare & Biotech
Hikma Pharmaceuticals said trading remains in line with expectations and narrowed its full-year 2026 core operating profit outlook. The company cited strong performance in its Branded business and improving profitability in Hikma Rx; no revised profit figures were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
HIK0.55
More News
- Hikma Pharmaceuticals narrows profit guidance, upgrades branded unit
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request